Specify a stock or a cryptocurrency in the search bar to get a summary
Biocon Limited
BIOCONBiocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India. Address: 20th KM Hosur Road, Bengaluru, India, 560100
Analytics
WallStreet Target Price
27 962.48 INRP/E ratio
26.7304Dividend Yield
0.15 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BIOCON
Dividend Analytics BIOCON
Dividend growth over 5 years
200 %Continuous growth
1 yearPayout Ratio 5 years average
18 %Dividend History BIOCON
Stock Valuation BIOCON
Financials BIOCON
Results | 2019 | Dynamics |